随着港股市场回暖，近年来，越来越多的内地企业选择香港作为其国际化的第一站，迈瑞医疗、美的集 团等大型企业相继在港股上市，赴港IPO再掀热潮。作为本次课程的"重头戏"，招银国际王冠老师和招 商银行贾素红老师分别分享了香港上市规则与流程以及跨境IPO服务方案、海问律所的陈敏老师和徐启 飞老师分享了赴港上市中国法律以及香港法律问题及解决方案、怀新投资赵小成老师分享了港股上市过 程中媒体关系管理要点。另外，毕马威关玉锋老师、冯炜老师分别就赴港上市的财务和税务问题和与会 企业做了精彩分享。最后，香港公司治理公会北京代表处首席代表高伟博士主持的圆桌论坛上，参会嘉 宾各方围绕晋港协同发展和赴港上市的核心问题及难点，就如何进一步加强两地资本市场互联互通、助 力更多优质企业利用港交所平台走向国际等议题展开了热烈讨论。（燕云） 11月21日，由山西省金融办、山西省商务厅指导，证券时报社联合香港公司治理公会、山西省上市公司 协会、招商银行太原分行等相关单位，在山西太原举办了晋港资本市场融合发展暨香港IPO辅导公开 课，吸引了70余家企业，共计100余人参会。 本次课程汇集了深港两地资本市场的政府职能部门，券商投行、投资咨询机构、会 ...

- The China Securities Biotechnology Theme Index was launched on August 26, 2015, by China Securities Index Co., Ltd. The index selects listed company securities involved in gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology as index samples to reflect the overall performance of biotechnology listed company securities[3][38] - The index sample space is the same as the China Securities All Index sample space, consisting of A-shares and depository receipts issued by red-chip companies that meet the following conditions: "(1) Non-ST, *ST securities; (2) Other securities: listed for more than one quarter, unless the average daily market value ranks in the top 30 since listing; (3) STAR Market and Beijing Stock Exchange securities: listed for more than one year and two years, respectively"[39] - The index sample selection method includes: (1) Ranking the securities in the sample space by average daily turnover over the past year and removing the bottom 20%; (2) Selecting biotechnology-related companies from the remaining securities as biotechnology theme candidates; (3) Ranking the candidates by average daily market value over the past year and selecting the top 50 securities as index samples[39] - The index's top ten constituent stocks are highly concentrated, focusing on the pharmaceutical industry. As of November 19, 2025, the top ten constituent stocks accounted for 55.26% of the total weight, forming a "CXO + innovative drugs + medical devices" golden triangle combination[40][41] - The index constituent stocks are evenly distributed across different market value ranges, with weights of 35.79% for stocks with a market value of over 100 billion, 44.24% for stocks with a market value between 200-1000 billion, and the rest distributed among other ranges[42][43] - The index constituent stocks are mainly concentrated in the biological medicine III, medical services, chemical preparations, and medical devices industries, with weights of 42.33%, 20.99%, 17.33%, and 11.97%, respectively[44][46] - The index constituent stocks have high exposure to concepts such as industry leaders, comprehensive private enterprises, main trading forces, dual circulation, fund heavy positions, and innovative drugs, with exposure rates of 70.56%, 64.78%, 64.58%, 62.60%, 62.48%, and 62.16%, respectively[47][48] - The index's current style is characterized by small market value, high liquidity, and high momentum. As of October 31, 2025, the index's market value style is significantly negatively exposed compared to the China Securities 800 Index, with higher liquidity and trading activity[48][51][52] - The index's PE valuation is near the historical average, and the PB valuation is near the historical -1 standard deviation, indicating a high safety margin and potential for upward valuation[53][54] - The index's profitability is outstanding, with expected revenue growth rates of 6.54%, 6.00%, and 13.76% for 2025, 2026, and 2027, respectively, and expected net profit growth rates of 52.09%, 18.58%, and 24.11% for the same years[55][56][57][58]

Core Insights - The Chinese medical device industry has entered a golden period of innovation, with more Chinese companies appearing in the global TOP 100 rankings and showing upward trends in their positions [2][4] - The overall market size of China's medical device industry is projected to reach 1.35 trillion yuan in 2024, making it the second-largest market globally [3] Group 1: Industry Growth and Innovation - Leading Chinese companies like Mindray, Weigao, and United Imaging have made significant strides, with 12 domestic firms entering the global TOP 100 list, and Mindray ranking 25th, up two spots from the previous year [4] - Over 50% of Mindray's profits now come from overseas markets, indicating a successful transition from a follower to a leader in specific segments [4] - The industry is experiencing a shift from imitation to innovation, driven by intense competition and the need for differentiation [4][5] Group 2: Collaborative Ecosystem - The collaboration between industry, hospitals, and research institutions is crucial for transforming innovative ideas into market-ready products [5] - The establishment of the Shanghai Clinical Innovation Transformation Research Institute exemplifies efforts to streamline the process from clinical needs to product development [5][6] Group 3: Regulatory and Institutional Innovations - The regulatory framework is evolving to support innovation, with a focus on adapting to new technologies like brain-computer interfaces and surgical robots [6] - Shanghai's Pudong New Area is leading in medical device regulatory reforms, aiming to transition from domestic replacement to global innovation standards [6][8] Group 4: Regional Development and Internationalization - Pudong has a solid medical device industry foundation, with over 500 R&D and manufacturing companies, accounting for 25% of the city's total [7] - The region has approved 38 innovative medical devices, representing about 10% of the national total, including several global firsts [7] - Pudong is also a hub for international collaboration, with over 200 foreign medical device companies and more than 60 local firms successfully entering international markets [7][8] Group 5: Future Plans and Strategic Initiatives - Pudong has launched a development plan for high-end medical devices from 2025 to 2027, focusing on innovation, park clustering, and ecosystem enhancement [8][9] - The area aims to become a global center for innovative medical devices and a preferred location for scientific entrepreneurship and regulatory reforms [9]

Core Viewpoint - Company maintains a strong commitment to R&D investment, allocating approximately 10% of annual revenue to R&D, which is among the highest in the medical device industry [1][2] Group 1: R&D Investment - Cumulative R&D investment reached 21.556 billion yuan since the company went public in 2018, reinforcing its core R&D capabilities for future growth [1] - The company emphasizes the importance of R&D innovation as a driving force, continuously increasing investment to develop market-relevant products [1] Group 2: Industry Challenges - The development of medical devices, such as defibrillators, involves a lengthy process, taking up to ten years from R&D to market launch, with five years dedicated to establishing certification standards [2] - The company acknowledges that technological breakthroughs in medical devices require a gradual accumulation of knowledge and cannot be achieved through shortcuts [2] Group 3: Future Directions - The company plans to enhance R&D innovation by developing higher-performance reagents and clearer imaging devices for early disease detection, as well as more precise and user-friendly minimally invasive instruments [2] - The goal is to improve healthcare quality and efficiency while reducing costs, ultimately extending quality healthcare to a broader population [2]

Core Viewpoint - The market experienced a significant downturn on November 21, with major indices declining, particularly the ChiNext Index which fell over 4% [1] Group 1: Market Performance - The ChiNext 50 ETF (159949) closed at 1.384 CNY, down 3.89% with a turnover rate of 9.89% and a trading volume of 2.429 billion CNY [1][2] - The ETF has seen a net inflow of 489 million CNY over the past five trading days, indicating positive investor sentiment despite the market decline [2][3] Group 2: ETF Details - As of November 20, 2025, the ChiNext 50 ETF has a total circulation scale of 25.25 billion CNY, leading among similar ETFs [2][3] - The top ten holdings of the ChiNext 50 ETF include leading companies such as CATL, Zhongji Xuchuang, and Dongfang Caifu, reflecting a focus on high-growth sectors [3] Group 3: AI Industry Insights - NVIDIA reported a quarterly revenue of 57 billion USD, a 62% year-over-year increase, and projected next quarter revenue to reach 65 billion USD, addressing concerns about AI asset price bubbles [4] - Analysts suggest that the AI industry is still in its early development stage, with significant long-term growth potential despite current high valuations [5] Group 4: Investment Strategies - The ChiNext 50 ETF (159949) is recommended as an efficient investment tool for those optimistic about the long-term growth of China's technology sector [5] - Investors are advised to consider dollar-cost averaging strategies to mitigate short-term volatility risks while monitoring the performance of index constituent stocks [5]

Investment Rating - The report maintains an "overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by more than 10% in the next six months [4][25]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index during the period from November 7 to November 20, 2025, with a decline of 1.51%, which is approximately 1.23 percentage points better than the CSI 300 index [11]. - Most sub-sectors within the industry recorded negative returns, with in vitro diagnostics and pharmaceutical distribution showing the highest gains of 2.37% and 2.27%, respectively, while medical R&D outsourcing and medical consumables experienced declines of 3.67% and 2.93% [12]. - Approximately 43% of stocks in the industry recorded positive returns during the same period, with the top performer, Hezhong China, seeing a weekly increase of 82.57% [16]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry as of November 20, 2025, was approximately 51.84 times, indicating a decrease in industry valuation [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a decline of 1.51% compared to the index's performance [11]. - Most sub-sectors recorded negative returns, with in vitro diagnostics and pharmaceutical distribution leading in gains [12]. - About 43% of stocks in the industry had positive returns, with significant variations in individual stock performance [16]. 2. Industry News - The report highlights the announcement from the Hebei Provincial Medical Products Procurement Center regarding the centralized procurement of 25 types of medical consumables, including biopsy needles and infusion ports [23]. 3. Company Announcements - Ningbo Tianyi Medical Devices Co., Ltd. received a medical device registration certificate for its blood dialysis concentrate products [24]. 4. Industry Outlook - The report suggests focusing on investment opportunities in the flu-related sector due to the onset of the flu season, recommending several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [25][27].

Group 1 - The medical sector showed signs of recovery, with major player United Imaging Healthcare rising over 3%, while other stocks like WuXi AppTec and Aier Eye Hospital fell more than 1% [1] - The largest medical ETF in A-shares (512170) experienced a decline of over 2.8% in the morning but recovered slightly in the afternoon, ultimately dropping over 1%, marking a four-month low [1] - A-shares' three major indices collectively fell over 2% [1] Group 2 - The medical ETF (512170) fell below its six-month moving average and approached a critical yearly support level, with significant trading volume of over 874 million yuan, setting a new monthly high for daily trading [3] - In the first four trading days of the week, over 627 million yuan flowed into the ETF, indicating potential bottom-fishing activity despite the risk of larger sell-offs [3] - The medical ETF has a current scale exceeding 25.3 billion yuan, making it the largest medical-related ETF in the market, with a focus on "medical devices + medical services" [3][4] Group 3 - The ETF's composition includes a significant weighting of over 26% in CXO, along with leading companies in aesthetic medicine, private hospitals, and medical information technology [3] - The ETF is passively tracking the CSI Medical Index, which was established on December 31, 2004, and published on October 31, 2014 [4]

Group 1: Economic Overview - In 2024, China's GDP is projected to exceed 134.9 trillion yuan, with a year-on-year growth of 5.0%, ranking among the top major economies globally [2] - The economic structure continues to optimize, with the primary industry accounting for 6.8%, secondary industry 36.5%, and tertiary industry 56.7% of GDP [2] - The three drivers of growth—consumption, investment, and exports—are working in synergy, contributing 2.2 percentage points, 1.3 percentage points, and 1.5 percentage points to GDP growth, respectively [2] Group 2: Technological Advancements - China is making significant breakthroughs in cutting-edge technologies such as 6G communication, AI large models, and quantum computing [3] - The first international 6G field test network was established in July 2024, demonstrating potential for 6G transmission capabilities [3] - By March 2025, a major breakthrough in quantum communication was achieved, establishing a comprehensive quantum communication network [3] Group 3: New Energy and Carbon Neutrality - The new energy sector is becoming a growth engine under the "dual carbon" goals, with China accounting for over 60% of global new installations in wind and solar energy in 2024 [4] - The installed capacity of new energy storage has surpassed 70 million kilowatts, with leading companies like CATL and BYD holding a 65.5% market share in the global power battery market [4] - Solid-state battery technology has achieved mass production breakthroughs, with energy density exceeding 400 Wh/kg, boosting the export of new energy vehicles to the world's highest volume [4] Group 4: Healthcare Sector - The aging population and health consumption upgrades are creating a trillion-yuan market, with national health expenditure reaching 2.03 trillion yuan in 2024 [5] - Technologies such as AI-assisted diagnosis, gene editing, and telemedicine are accelerating implementation, with companies like WuXi AppTec and Mindray Medical expanding globally [5] Group 5: Financial and Consumer Trends - The financial sector is progressing steadily amid strict regulations and digitalization, with total assets of financial institutions reaching 495.59 trillion yuan, a 7.5% year-on-year increase [6] - The banking sector's total assets amounted to 444.57 trillion yuan, growing by 6.5% [6] - In the consumer market, new retail and domestic brands are rising, with companies like Luckin Coffee and Pop Mart reshaping market dynamics through data-driven and IP operations [6] Group 6: Emerging and Future Industries - Emerging and future industries are seen as drivers of economic growth and international competitiveness, with the low-altitude economy projected to reach a market size of 1.5 trillion yuan by 2025 [7] - The embodied intelligence market is expected to exceed 480 billion yuan in 2024, with significant growth anticipated in smart manufacturing and services [7] Group 7: Super CEO Selection - The "2025 Super CEO" selection is open to all outstanding enterprises in China, covering both listed and unlisted companies [8] - The evaluation criteria include company size (25%), financial performance (40%), shareholder returns (20%), and personal reputation (15%) [8] - A total of 288 CEOs have entered the candidate pool, with the final list to feature the top 25 CEOs [8]

Core Viewpoint - The merger between Mindray Medical and Huatai Medical is a landmark event in the STAR Market, showcasing the integration of quality resources and accelerating technological iteration in the medical device industry [2][3]. Group 1: Strategic Alignment and Integration - The successful integration of Mindray Medical and Huatai Medical is attributed to strategic alignment and natural synergy in technology and products, which serves as a foundation for deep collaboration [3]. - The merger established a clear business development strategy, with Mindray sending a dedicated team to Huatai for in-depth collaboration, creating a strategic development blueprint that leverages each company's strengths [3][4]. - The focus on resource investment is crucial for achieving synergy, with the integration process requiring the deployment of elite teams to ensure high-quality value creation [3][4]. Group 2: Performance and Growth - In the nearly 19 months since the merger, both companies have concentrated on the high-growth, high-barrier, and low domestic penetration market of three-dimensional atrial fibrillation systems, leveraging Huatai's strengths in consumables and Mindray's advantages in complex system development [4]. - Huatai Medical reported revenue of 1.867 billion yuan, a year-on-year increase of 22.47%, and a net profit of 623 million yuan, up 18.02% year-on-year for the first three quarters of 2025, indicating the effectiveness of the merger [5]. - The company plans to continue increasing R&D investment, focusing on core areas to achieve higher quality growth, as there remains a gap compared to leading international competitors [5]. Group 3: R&D and Innovation - The core of the merger's success lies in R&D collaboration and technological upgrades in the electrophysiology field, with Huatai Medical significantly increasing its R&D investment [5][6]. - Huatai Medical has established itself as a pioneer in the domestic market for electrophysiology products, with multiple core technologies under development [6]. - The company aims to balance rapid iteration with risk control by creating a reusable general technology platform, which will lower innovation costs and ensure risk management [6]. Group 4: Globalization Strategy - The deepening of industry integration necessitates Huatai Medical's global expansion, with a focus on building a standardized operational system that aligns with international market rules [8][9]. - The company emphasizes the importance of understanding local market demands and developing products that meet these needs, rather than simply reusing Mindray's global channels [8][9]. - Huatai Medical's future international strategy includes enhancing product competitiveness and establishing localized supply chain capabilities to penetrate developed markets [10].

Core Viewpoint - The merger between Mindray Medical and Huatai Medical is a landmark event in the STAR Market, showcasing the integration of high-quality resources and accelerating technological iteration in the medical device industry [1][2]. Strategic Leadership - The successful integration of Mindray Medical and Huatai Medical is attributed to their strategic alignment and natural synergy in technology and products, establishing a benchmark for industry mergers [1][2]. - Mindray Medical's immediate deployment of a skilled team to Huatai Medical post-merger facilitated deep integration and the development of a strategic blueprint, enhancing collaboration and resource sharing [2]. Performance Metrics - Huatai Medical achieved revenue of 1.867 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 22.47%, with a net profit of 623 million yuan, up 18.02% [3]. - The collaborative efforts led to the successful launch of the PFA and RFA three-dimensional atrial fibrillation systems, positioning Huatai Medical among the top tier of domestic electrophysiology equipment [3]. R&D Focus - The core of the merger's success lies in the collaborative R&D efforts in the electrophysiology sector, with Huatai Medical increasing its R&D investment to 98 million yuan in the third quarter of 2025, representing a 14.98% R&D expense ratio [3][4]. - Huatai Medical has established itself as a leader in R&D within the domestic market, maintaining an R&D expense ratio exceeding 14% over the past five years [4]. Innovation and Growth - The company aims to innovate in two main areas: deepening innovation in electrophysiology and upgrading consumables through material modification and design optimization [5]. - Huatai Medical's strategy includes building a reusable technology platform to balance rapid iteration with risk control, leveraging Mindray Medical's established systems [4][5]. Globalization Strategy - The integration with Mindray Medical is seen as a stepping stone towards international expansion, with a focus on developing a standardized global operational framework [6]. - Huatai Medical plans to enhance its international market presence by understanding local clinical needs and building localized supply chain capabilities [6][7]. Conclusion - The development trajectory of Huatai Medical illustrates the synergistic value of industrial integration and highlights the potential for Chinese enterprises to innovate and expand globally [7].